Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 20/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 20/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271473 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824244 | 1.00 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL825369 | 0.92 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816903 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816901 | 0.91 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824288 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824281 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL14189759 | 0.88 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4816683 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4824255 | 0.88 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019030-B2 | Cyano and carboxy derivatives of substituted styrenes; inhibitors of tumor necrosis factor alpha, nuclear factor kappa B, and phosphodiesterase | CELGENE CORPORATION (US) | 2006-03-28 | — | — | US | claimed |
| US-20040019106-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2004-01-29 | — | — | US | claimed |
| CN-119504492-A | Method for synthesizing alkenyl nitrile compound by manganese-based catalyst | 西安近代化学研究所 | 2025-02-25 | — | — | CN | disclosed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-3904875-B1 | METHODS FOR DETERMINING DRUG EFFICACY USING IKZF3 (AIOLOS) | CELGENE CORP (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3313818-B1 | METHODS FOR THE TREATMENT OF KAPOSI'S SARCOMA OR KSHV-INDUCED LYMPHOMA USING IMMUNOMODULATORY COMPOUNDS, AND USES OF BIOMARKERS | CELGENE CORP (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-08-24 | — | — | US | disclosed |
| WO-2023158514-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023149801-A1 | METHOD FOR PREPARING A CONFORMATION-SPECIFIC ANTIBODY. | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2023-08-10 | — | — | WO | disclosed |
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CELGENE CORPORATION | 2022-10-13 | — | — | US | disclosed |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CELGENE CORPORATION (US) | 2022-08-23 | — | — | US | disclosed |
| EP-0918746-B1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-6479554-B2 | CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. | CELGENE CORPORATION | 2002-11-12 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324991-A1 | BCMA-BINDING ANTIBODIES AND USES THEREOF | CD79B, BCL6, CD22 | PDE4A 4566/4885PDE4B 4638/4885PDE4C 4515/4885 |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | PLK2, PLK4, PLK1 | PDE4A 2324/4885PDE4B 2388/4885PDE4C 2581/4885 |
| US-11419861-B2 | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases | CRBN, UBQLN1, UBQLN2 | PDE4A 3511/4885PDE4B 3182/4885PDE4C 3458/4885 |
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | PDE4A 22/4885PDE4B 33/4885PDE4C 39/4885 |
| US-20040019106-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | PDE4A 22/4885PDE4B 33/4885PDE4C 39/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | PDE4A 22/4885PDE4B 33/4885PDE4C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.